Noble Financial Releases a Buy Rating on ContraVir Pharmaceuticals Inc

By Austin Angelo

In a report released yesterday, Mark Jordan from Noble Financial reiterated a Buy rating on ContraVir Pharmaceuticals Inc (NASDAQ: CTRV). The company’s shares closed yesterday at $1.50.

According to TipRanks.com, Jordan is a 1-star analyst with an average return of -1.6% and a 36.7% success rate. Jordan covers the Technology sector, focusing on stocks such as Comtech Telecommunications, OmniComm Systems Inc, and Innodata Isogen Inc.

ContraVir Pharmaceuticals Inc has an analyst consensus of Moderate Buy.

Based on ContraVir Pharmaceuticals Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $7.62 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $3.92 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ContraVir Pharmaceuticals, Inc. is a development stage biopharmaceutical company which is focused primarily on the development of drugs to treat herpes zoster or shingles. The company currently developing a compound called FV-100 for the treatment of shingles. It is also developing CMX157, a potent analog of the successful antiviral drug tenofovir DF. ContraVir Pharmaceuticals was founded on May 15, 2013 and is headquartered in Edison, NJ.